WSGR logoWSGR logo
Christina Fuleihan
Associate
Technology Transactions
Boston

D617-598-7822

Download vCard
Open PDF

Christina Fuleihan is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the Technology Transactions practice. She focuses on the representation of pharmaceutical, biotechnology, and medical device companies in various intellectual property and commercial transactions, including licensing and strategic alliances.

During law school, Christina also obtained a graduate degree in public health. Her research into the activities of public health agencies during the COVID-19 pandemic received awards through the AUWCL National Health Law Writing Competition and Food and Drug Law Institute’s Austern Writing Competition.

Experience

Christina Fuleihan is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the Technology Transactions practice. She focuses on the representation of pharmaceutical, biotechnology, and medical device companies in various intellectual property and commercial transactions, including licensing and strategic alliances.

During law school, Christina also obtained a graduate degree in public health. Her research into the activities of public health agencies during the COVID-19 pandemic received awards through the AUWCL National Health Law Writing Competition and Food and Drug Law Institute’s Austern Writing Competition.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly
On January 7, 2026, Eli Lilly and Company announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases. Under the terms of the agreement, Lilly will acquire all the outstanding shares of Ventyx in an all-cash transaction, valuing at approximately $1.2 billion. Wilson Sonsini is advising Ventyx on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.

The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Learn More
View All
Recent Events
Affiliated Programs
American Cancer Society BrightEdge Entrepreneurs 2025 Pitch Event
Wilson Sonsini is a proud sponsor of the American Cancer Society BrightEdge Entrepreneurs Pitch Event.
Learn More
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.